2. Kulchavenya E.V., Holtobin D.P., Shevchenko S.Yu., Potapov V.V., Zulin Ya.V.The frequency of chronic prostatitis in the structure of outpatient urological admission. Experimental and Clinical Urology. 2015; 1: 16-19. Russian (Кульчавеня Е.В., Холтобин Д.П., Шевченко С.Ю., Потапов В.В.,Зулин Я.В. Частота хронического простатита в структуре амбулаторного урологического приема. Экспериментальная и клиническая урология. 2015;1:16–19).

3. Harnett M.D., Shipley J., MacLean L., Schwiderski U., Sandage B.W. Jr. Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects. Clin Drug Investig. 2013;33(2):133–141. Doi: 10.1007/s40261-012-0039-8

4. Chancellor M.B., Migliaccio-Walle K., Bramley T.J., Chaudhari S.L., Corbell C., Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744–1751. Doi: 10.1016/j.clinthera.2013.08.017

5. Kuzmin I.V. Epidemiological aspects of overactive bladder and urgency urinary incontinence. Urological statements. 2015; 5(3):30–34. Russian (Кузьмин И.В. Эпидемиологические аспекты гиперактивного мочевого пузыря и ургентного недержания мочи. Урологические ведомости. 2015;5(3):30–34). Doi: 10.17816/uroved5330-34

6. Tae B.S., Park T.Y., Jeon B.J., et al. Seasonal Variation of Overactive Bladder Symptoms in Female Patients. Int Neurourol J. 2019;23(4):334–340. Doi:10.5213/inj.1938078.039.

7. Eapen R.S., Radomski S.B. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71–76. Doi: 10.2147/RRU.S102441.

8. Aoki Y., Brown H.W., Brubaker L., Cornu J.N., Daly J.O., Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. doi: 10.1038/nrdp.2017.42. Erratum in: Nat Rev Dis Primers. 2017 Nov 16;3:17097.

9. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147 Suppl 2(Suppl 2):S80–S87. Doi: 10.1038/sj.bjp.0706560.

10. Inoue M., Yokoyama T. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. Acta Med Okayama. 2019;73(5):387–392. Doi:10.18926/AMO/57368.

11. Govender Y., Gabriel I., Minassian V., Fichorova R. The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women. Front Cell Infect Microbiol. 2019;9:133. Doi: 10.3389/fcimb.2019.00133.

12. Lee C.K., Tsai C.P., Liao T.L., Huang W.N., Chen Y.H., Lin C.H., Chen Y.M. Overactive bladder and bladder pain syndrome/interstitial cystitis in primary Sjögren’s syndrome patients: A nationwide population-based study. PLoS One. 2019;14(11):e0225455. Doi: 10.1371/journal.pone.0225455.

13. Shin J.H., Ryu C.M., Yu H.Y., Shin D.M., Choo M.S. Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction. Stem Cell Rev Rep. 2020;16(1):82–93. Doi: 10.1007/s12015-019-09922-2.

14. Levy G., Lowenstein L. Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review. Sex Med. 2020;8(1):1–7. Doi: 10.1016/j.esxm.2019.08.013.

15. Ergenoglu A.M., Yeniel A.Ö., Itil I.M., Askar N., Meseri R., Petri E. Overactive bladder and its effects on sexual dysfunction among women. Acta Obstet Gynecol Scand. 2013;92(10):1202-7.

16. Serati M., Salvatore S., Uccella S., Nappi R.E., Bolis P. Female urinary incontinence during intercourse: a review on an understudied problem for women’s sexuality. J Sex Med. 2009;6(1):40–48.

17. El-Azab A.S., Yousef H.A., Seifeldein G.S. Coital incontinence: relation to detrusor overactivity and stress incontinence. Neurourol Urodyn. 2011;30(4):520–524.

18. Luchinsky S.A. Pharmacological correction of sexual dysfunctions in women with overactive bladder. abstract dis. Ph.D. Pacific. state honey. un-t. Vladivostok, 2015. (in Russian). Лучинский С.А. Фармакологическая коррекция сексуальных дисфункций у женщин с гиперактивным мочевым пузырем. автореферат дисc. кандидата медицинских наук / Тихоокеан. гос. мед. ун-т. Владивосток, 2015.

19. Danilov V.V., Danilov V.V., Danilov V.V. Overactive bladder syndrome and female sexual dysfunction. Polyclinic doctor’s reference book. 2018;2:53–57. Russian (Данилов В.В., Данилов В.В., Данилов В.В. Синдром гиперактивного мочевого пузыря и женские сексуальные дисфункции. Справочник поликлинического врача. 2018. № 2. С. 53–57).

20. Danilova T.I., Danilov V.V., Luchinsky S.A. Urinary disorders and sexual dysfunctions in women: issues of prescribing m-anticholinergic spasmex. Pharmateca. 2012;12 (245):90–95. Russian (Данилова Т.И., Данилов В.В., Лучинский С.А. Расстройства мочеиспускания и сексуальные дисфункции у женщин: вопросы назначения м-холинолитика спазмекса. Фарматека. 2012;12:90–95).

21. Geoffrion R. Urogynaecology committee. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can. 2012;34(11):1092–1101. Doi:10.1016/S1701-2163(16)35440-8.

22. Szymański JK, Słabuszewska-Jóźwiak A, Zaręba K, Jakiel G. Neuromodulation – a therapeutic option for refractory overactive bladder. A recent literature review. Wideochir Inne Tech Maloinwazyjne. 2019;14(4):476–485. Doi:10.5114/wiitm.2019.85352.

23. Chen J..L, Kuo H.C. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33–S42. Doi: 10.4111/icu.2020.61.S1.S33.

24. Wang C.C., Jiang Y.H., Kuo H.C. The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A. Toxins (Basel). 2020;12(3):186. Published 2020 Mar 16. Doi: 10.3390/toxins12030186.

25. Huang A.J., Grady D., Mendes W.B., Hernandez C., Schembri M., Subak L.L. A Randomized Controlled Trial of Device Guided, Slow-Paced Respiration in Women with Overactive Bladder Syndrome. J Urol. 2019;202(4):787–794. Doi:10.1097/JU.0000000000000328.

26. Shen J., Luo R., Zhang L., Li Y., Ke L., Gao Z. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: A case report. Medicine (Baltimore). 2019;98(45):e17795. Doi:10.1097/MD.0000000000017795.

27. Bhide A.A., Tailor V., Fernando R., Khullar V., Digesu G.A. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Int Urogynecol J. 2020;31(5):865-870. Doi: 10.1007/s00192-019-04186-3.

28. Zhu Y., Zhu Z., Chen J. Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes. Int J Clin Pract. 2019;73(11):e13395. Doi: 10.1111/ijcp.13395

29. Hagovska M., Švihra J., Buková A., et al. The Relationship between Overweight and Overactive Bladder Symptoms. Obes Facts. 2020;13(3):297–306. doi:10.1159/000506486

30. Umek W., Gleiss A., Bodner-Adler B., Reichardt B., Rinner C., Heinze G. The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study. Pharmacoepidemiol Drug Saf. 2020;29(2):189–198. Doi: 10.1002/pds.4920

31. Wróbel A., Serefko A., Woźniak A., et al. Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways. Pharmacol Biochem Behav. 2020;189:172842. Doi: 10.1016/j.pbb.2019.172842

32. Kuzmin I.V., Al-Shukri SKh. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St. Petersburg). 2020;10(2):163–171. Russian (Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты. Урологические ведомости. 2020;10(2): 163–171). Doi: 10.17816/uroved102163-171.

33. Hsiao S.M., Lin H.H. Medical treatment of female overactive bladder syndrome and treatment-related effects. J Formos Med Assoc. 2018;117(10):871–878. Doi: 10.1016/j.jfma.2018.01.011.

34. Polat S., Yonguc T., Yarimoglu S., Bozkurt I.H., Sefik E., Degirmenci T. Effects of the transobturator tape procedure on overactive bladder symptoms and quality of life: a prospective study. Int Braz J Urol. 2019;45(6):1186–1195. Doi:10.1590/S1677-5538.IBJU.2019.0158.

35. Okui N. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. World J Urol. 2019;37(11):2459–2466. Doi:10.1007/s00345-019-02644-7

36. Kakizaki H., Lee K.S., Yamamoto O., et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2020;6(4):729–737. Doi:10.1016/j.euf.2019.10.019

37. Kosilov K.V., Loparev S.A., Ivanovskaya M.A., Kosilova L.V. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia. Am J Mens Health. 2016 Mar;10(2):157–163. Doi: 10.1177/1557988315595692.

38. Yoshida M., Takeda M., Gotoh M., et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125(5):709–717. Doi:10.1111/bju.15020

39. Huang C.K., Lin C.C., L.in A.T. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep. 2020;10(1):11355. Published 2020 Jul 9. Doi:10.1038/s41598-020-68170-4.

40. Wagg A., Staskin D., Engel E., Herschorn S., Kristy R.M., Schermer C.R. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–220. Doi:10.1016/j.eururo.2019.10.002.41. Griebling T.L., Campbell N.L., Mangel J., et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109. Doi:10.1186/s12877-020-1474-7.

42. Makhani A., Thake M., Gibson W. Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient. Clin Interv Aging. 2020;15:575–581. Doi:10.2147/CIA.S174402.

43. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27(2):144–153. Doi: 10.1016/j.clinthera.2005.02.014.

44. Kerdraon J., Robain G., Jeandel C., et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol. 2014;24(11):672–681. Doi: 10.1016/j.purol.2014.06.003.

45. Chancellor M.B., Staskin D.R., Kay G.G., Sandage B.W., Oefelein M.G., Tsao J.W. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

46. Staskin D.R. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013–1028. Doi:10.2165/00002512-200522120-00003.

47. Chancellor M., Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–174. Doi:10.1111/j.1755-5949.2011.00248.x.

48. Araklitis G., Robinson D., Cardozo L. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clin Interv Aging. 2020;15:1493–1503. Doi:10.2147/CIA.S252852

49. Biastre. K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009;43(2):283–295. Doi:10.1345/aph.1L160.

50. McFerren S.C., Gomelsky A. Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs Aging. 2015;32(10):809–819. Doi:10.1007/s40266-015-0301-x

51. Oefelein M.G. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf. 2011;34(9):733–754. Doi:10.2165/11592790-000000000-00000.

52. Sand P.K., Johnson Ii T.M., Rovner E.S., Ellsworth P.I., Oefelein M.G., Staskin D.R. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome. BJU Int. 2011;107(4):612–620. Doi:10.1111/j.1464-410X.2010.09519.x.

53. Notz H.J., Hautumm B., Werdier D., Groves R., Odenthal K.P. Trospium chlorid als Einmalgabe bei überaktiver Blase: Ergebnisse einer multizentrischen Beobachtungsstudie

54. Zinner N.R., Dmochowski R.R., Staskin D.R., Siami P.F., Sand P.K., Oefelein M.G. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30(7):1214–1219. Doi:10.1002/nau.21000.

55. Geller E.J., Crane A.K., Wells E.C., et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig. 2012;32(10):697–705. Doi:10.2165/11635010-000000000-00000.

56. Geller E.J., Dumond J.B., Bowling J.M., et al. Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–123. Doi:10.1097/SPV.0000000000000374.

57. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract. 2010;64(11):1535–1540. Doi: 10.1111/j.1742-1241.2010.02493.x.

58. Srivastava V.K., Agrawal S., Deshmukh S.A., Noushad F., Khan S., Kumar R. Efficacy of trospium for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Korean J Anesthesiol. 2020;73(2):145–150. Doi:10.4097/kja.19198.

59. Kulchavenya E.V., Brizhatyuk E.V. Bladder tuberculosis: diagnosis and treatment. Urologiia. 2006;3:61–65. Russian (Кульчавеня Е.В., Брижатюк Е.В. Туберкулез мочевого пузыря: диагностика и лечение. Урология. 2006;3:61–65).

60. Kulchavenya E., Naber K., Bjerklund Johansen T.E. Urogenital tuberculosis: classification, diagnosis, and treatment. European Urology Supplement. 2016;15(4):112–121.